Abstract
A double-blind cross-over trial comparing oral fluphenazine and fluphenazine enanthate in 43 chronic in-patient male schizophrenics showed that both were efficacious. On the total score assessment fluphenazine was statistically superior to fluphenazine enanthate, but the overall clinical impression showed a slight superiority for fluphenazine enanthate. Fewer patients needed anti-parkinson medication during the trial period. Patients were as adequately controlled as they had been before the trial on a variety of phenothiazines. The results are discussed, and important factors, such as the certainty that the patients are receiving their medication with the long-acting injection and the saving of time for overworked nursing staff, are stressed.

This publication has 15 references indexed in Scilit: